Medications for Generalized Anxiety Disorder: Neurobiology
This paper examines the pharmacological treatment of Generalized Anxiety Disorder (GAD), focusing on the neurobiology and mechanisms of action of two primary medication classes: antidepressants and benzodiazepines. Within antidepressants, the paper discusses selective serotonin reuptake inhibitors (SSRIs) — including fluoxetine, sertraline, paroxetine, and citalopram — and selective serotonin-norepinephrine reuptake inhibitors (SNRIs), specifically venlafaxine and duloxetine. It also covers benzodiazepines, particularly alprazolam, which is the only FDA-approved drug in that class for GAD. The paper concludes by noting that combining pharmacotherapy with cognitive behavioral therapy may yield the best outcomes for patients.
- Introduction: Defines GAD and scopes pharmacological discussion
- Antidepressants as First-Line GAD Medications: Overview of antidepressants as primary GAD treatment
- Selective Serotonin Reuptake Inhibitors (SSRIs): Mechanisms and examples of SSRI drugs
- Selective Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs): Venlafaxine and duloxetine mechanisms and efficacy
- Benzodiazepines in GAD Treatment: GABA-based CNS depressants and FDA approvals
- Conclusion: Combined pharmacotherapy and psychotherapy outcomes
✍️ How to write this paper — guide, tools & examples ▾
What makes this paper effective
- Organizes a complex pharmacological topic into clearly delineated medication classes, making the material accessible and logically progressive.
- Consistently pairs drug names with their specific mechanisms of action, grounding clinical claims in neurobiological explanation.
- Distinguishes between FDA-approved and off-label uses, demonstrating awareness of regulatory context alongside clinical evidence.
Key academic technique demonstrated
The paper effectively uses comparative analysis to differentiate between medication classes — for example, contrasting SSRIs (serotonin only) with SNRIs (serotonin and norepinephrine) and benzodiazepines (GABA modulation) — helping readers understand not just what each drug does, but how the classes relate to one another neurobiologically.
Structure breakdown
The paper follows a clear hierarchical structure: a brief introduction defines GAD and scopes the discussion; the body moves from antidepressants (subdivided into SSRIs and SNRIs, each with drug-by-drug breakdowns) to benzodiazepines; and a short conclusion situates pharmacotherapy within the broader treatment landscape including psychotherapy. This scaffold mirrors a clinical review format appropriate for a psychobiology course.
Introduction
From time to time, most people feel anxious about diverse events or occurrences in life — this is normal. However, when anxiety is persistent, exaggerated, and/or excessive, a person may be suffering from Generalized Anxiety Disorder (GAD). In the past, various interventions have been formulated in an attempt to treat this condition. The main treatment approaches are medications and psychotherapy. This paper concerns itself with the medications approved in the treatment of GAD, with the main focus on neurobiology and drug mechanisms of action.
Antidepressants as First-Line GAD Medications
There are various medications that have proven effective and have thus been approved for the treatment of GAD. These medications are especially instrumental in efforts to ease symptoms of the condition. The two major medication classes considered here are antidepressants and benzodiazepines.
As Gerlach and Gloster (2020) point out, antidepressants are considered first-line medications in the treatment of GAD — that is, they are routinely used as the first choice of medication for patients diagnosed with the condition. Unlike benzodiazepines, which are usually used for short-term treatment, antidepressants are employed in the longer-term management of GAD. Two important antidepressant subclasses in this context are selective serotonin reuptake inhibitors (SSRIs) and selective serotonin-norepinephrine reuptake inhibitors (SNRIs).
References
Durbano, F. (2013). New Insights into Anxiety Disorders. BoD.
Gerlach, A. & Gloster, A. (2020). Generalized Anxiety Disorder and Worrying: A Comprehensive Handbook for Clinicians and Researchers. John Wiley & Sons.
Marker, C. & Aylward, A. (2011). Generalized Anxiety Disorder. Hogrefe Publishing.
Schlaepfer, T. E. & Nemeroff, C. B. (2012). Neurobiology of Psychiatric Disorders. Elsevier.
Strawn, J. R., Geracioti, L., Tajdev, N., Clemenza, K., & Levine, A. (2019). Pharmacotherapy for generalized anxiety disorder in adults and pediatric patients: An evidence-based treatment review. Expert Opinion on Pharmacotherapy, 19(10), 1057–1070.
Create your account
Always verify citation format against your institution’s current style guide requirements.